ADITYA CHOPRA: Open Payments
NPI 1508850991 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,229 in 196 payments from 34 companies in 2025. Trend: 2023 $17,894 · 2024 $8,413 · 2025 $9,229
Speaker / faculty: $4,613Food & beverage: $4,546Education: $70
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $4,998 |
| AstraZeneca Pharmaceuticals LP | 12 | $665 |
| GlaxoSmithKline, LLC. | 11 | $325 |
| PFIZER INC. | 14 | $324 |
| Sumitomo Pharma America, Inc. | 9 | $220 |
| Amgen Inc. | 13 | $213 |
| Lilly USA, LLC | 8 | $191 |
| Lundbeck LLC | 12 | $176 |
| Phathom Pharmaceuticals, Inc. | 9 | $168 |
| Astellas Pharma US Inc | 6 | $161 |
Products named: QULIPTA, UBRELVY, REXULTI, AIRSUPRA, BREZTRI, GEMTESA, TRELEGY ELLIPTA, VOQUEZNA.
Industry payments across MD — which companies pay providers there.
